Cargando…

Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report

Tumour lysis syndrome (TLS) represents a group of fatal metabolic derangements resulting from the rapid breakdown of tumour cells. TLS typically occurs soon after the administration of chemotherapy in haematologic malignancies but is rarely observed in solid tumours. Here, we report a case of brigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yadong, Wang, Tiange, Xue, Jianchao, Jia, Ziqi, Liu, Xinyu, Li, Bowen, Li, Ji, Li, Xiaoguang, Wang, Weiwei, Bing, Zhongxing, Cao, Lei, Cao, Zhili, Liang, Naixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721166/ https://www.ncbi.nlm.nih.gov/pubmed/34987411 http://dx.doi.org/10.3389/fphar.2021.809467

Ejemplares similares

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
por: Bing, Zhongxing, et al.
Publicado: (2021)

Novel ALK mutation with durable response to brigatinib—a case report
por: Latif, Hira, et al.
Publicado: (2020)

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy
por: Gerthofer, Valeria, et al.
Publicado: (2021)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Li, Shuluan, et al.
Publicado: (2021)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Clinical implications of EGFR‐associated MAPK/ERK pathway in multiple primary lung cancer
por: Liang, Naixin, et al.
Publicado: (2022)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
por: Ali, Robert, et al.
Publicado: (2019)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
por: Sabari, Joshua K, et al.
Publicado: (2017)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
por: Jiang, Wei, et al.
Publicado: (2020)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective
por: Cranmer, Holly, et al.
Publicado: (2022)

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
por: Carcereny, Enric, et al.
Publicado: (2021)

Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients
por: Cao, Lei, et al.
Publicado: (2022)

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK
por: Chang, Long-Sheng, et al.
Publicado: (2021)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis
por: Xue, Jianchao, et al.
Publicado: (2022)

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer
por: Yang, Huaxia, et al.
Publicado: (2021)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC
por: Gupta, Neeraj, et al.
Publicado: (2022)

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
por: Wang, Yadong, et al.
Publicado: (2022)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019)

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
por: Xiao, Zhiwei, et al.
Publicado: (2020)

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
por: Yoshida, Tatsuya, et al.
Publicado: (2023)

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
por: Camidge, D. Ross, et al.
Publicado: (2020)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
por: Guo, Aofeng, et al.
Publicado: (2020)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain, Rohit K, et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
por: Gettinger, Scott N., et al.
Publicado: (2022)

Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation
por: Song, Yang, et al.
Publicado: (2023)

Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy
por: Zhang, Zhe, et al.
Publicado: (2019)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
por: Wakuda, Kazushige, et al.
Publicado: (2023)

First-line treatment selection with organoids of an EGFRm + TP53m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up
por: Jia, Ziqi, et al.
Publicado: (2020)

Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report
por: Nakashima, Koki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jmnrjqbpsqt0d7279e0ibvbhhp